Two National Guard members shot near White House
NEW YORK - Morgan Stanley & Co. LLC disclosed on Wednesday its trading activity in Avadel Pharmaceuticals plc (NASDAQ:AVDL) shares, reporting purchases of 197,001 ordinary shares and sales of 188,943 shares on November 25, 2025.
According to the regulatory filing submitted to the Irish Takeover Panel under Rule 38.5(a), the transactions were executed at prices ranging between $22.88 and $22.99 per share.
The disclosure identifies Morgan Stanley & Co. LLC as an exempt principal trader with recognized intermediary status dealing in a client-serving capacity. The firm is connected to Avadel Pharmaceuticals plc in relation to an unspecified offer or potential transaction.
The filing was made in compliance with the Irish Takeover Panel Act, 1997, Takeover Rules, 2022, which requires disclosure of dealings by connected exempt principal traders.
No cash-settled derivative transactions, stock-settled derivative transactions, or other dealings were reported in the disclosure. The filing also noted there were no indemnity arrangements or agreements relating to options or derivatives.
The information was released through the Regulatory Information Service of the London Stock Exchange, as required for public disclosures under Rule 38 of the Irish Takeover Rules.
This article is based on a regulatory disclosure statement filed by Morgan Stanley & Co. LLC.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.